|Mode of transmission||By respiratory droplets or direct contact with nasopharyngeal secretions from a carrier or case.|
|Incubation period||2–10 days, commonly 3–4 days.|
|Period of communicability||Therapy with rifampicin, ceftriaxone or ciprofloxacin eradicates N. meningitidis from mucosal surfaces within 24 hours, and the case is no longer considered infectious.|
|Suspected cases||Administer antibiotics as soon as possible (prior to transport to hospital). |
Notify all suspected cases as soon as possible.
|Available vaccines||Meningococcal group C conjugate (MenCCV): NeisVac-C. |
Quadrivalent meningococcal conjugate (MCV4): Menactra (MCV4-D) – conjugated to diphtheria toxoid; Nimenrix (MCV4-T) – conjugated to tetanus toxoid.
Quadrivalent meningococcal polysaccharide (4vMenPV): Mencevax ACWY.
|Funded vaccine indications||MCV4-D (Menactra) or MenCCV (NeisVac-C) for : |
|Vaccine efficacy/effectiveness||Meningococcal conjugate vaccines are preferred over polysaccharide vaccines because they allow vaccination in younger children and are associated with the development of herd immunity.|
|Precaution||Individuals with a history of Guillain-Barré syndrome who are considering immunisation with MCV4-D.|
|Management of close contacts||Antibiotic prophylaxis – preferably within 24 hours of the initial diagnosis, but recommended up to 14 days after the diagnosis of illness.|